Evaluating the Murine Anti-Human Antibody Response and Assessment of General Activity and Cognition after Treatment with Human Intravenous Immunoglobulins in Healthy Adult C57/B6J Mice

Abstract

Human intravenous immunoglobulin (IVIG) is a fractionated blood product that is used for the treatment of several autoimmune and immunodeficiency disorders. Recently, IVIG has been suggested for the treatment of Alzheimer's disease (AD). However, the molecular mode of action is still largely unknown. Therefore, preclinical assessment of the therapeutic efficacy of IVIG in animals may provide valuable information of the function of IVIG in vivo. However, it is recommended to determine the murine-anti-human antibody (MAHA) response in those animals before starting immunotherapy and subsequent assessment of the therapeutic efficacy in animal models for AD. After weekly administration of 400 μg IVIG in C57/B6J mice for the duration of twelve weeks, we found a significant increase of MAHA response against human IgG. Even after increased MAHA levels starting from week nine after treatment, there was no significant change in basic exploratory behavior, anxiety, and cognition. Therefore, it is suitable to study pharmacological and immunological activity, therapeutic efficacy, as well as mode of action of IVIG in animal models only for a short duration to avoid interference with IVIG treatment and neutralize possible therapeutic effects.

Keywords

intravenous immunoglobulin Alzheimer's disease MAHA immunization behavior cognition murine anti-human antibodies immunotherapy

References

Klee

. Human anti-mouse antibodies. Arch Pathol Lab Med 2000; 124:921–23.

Ochsenbein

. Monoklonale Antikoerper als therapeutische Substanzen. Schweiz Med Forum 2008; 8:140–43.

Imboden

Murphy

Rakhmilevich

Neal

Xiang

Reisfeld

Gillies

Sondel

. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy. Cancer Res 2001; 61:1500–7.

Loeffler

Smith

Klaver

Brzezinski

Morrison

Coffey

Steficek

Cook

. Development of antihuman IgG antibodies and hematologic deficits but not clinical abnormalities in C57BL/6 mice after repeated administration of human intravenous immunoglobulin. Comp Med 2012; 62:31–36.

Ephrem

Chamat

Miquel

. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: A critical factor in controlling experimental autoimmune encephalomyelitis. Blood 2008; 111:715–22.

Roy

Stavropoulos

Brennan

. Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice. Infect Immun 2005; 73:6101–9.

Olivieri

Vasconcellos

Nobrega

Minoprio

Kaveri

Araujo-Jorge

. Intravenous immunoglobulin increases survival time in the acute phase of experimental Chagas disease. Parasite Immunol 2010; 32:464–69.

Dodel

Balakrishnan

Keyvani

. Naturally occurring autoantibodies against beta-amyloid: Investigating their role in transgenic animal and in vitro models of Alzheimer's disease. J Neurosci 2011; 31:5847–54.

Mengel

Röskam

Neff

. Naturally occurring autoantibodies interfere with β-amyloid metabolism and improve cognition in a transgenic mouse mouse model of Alzheimer's disease 24 h after single treatment. Transl Psychiatry 2013; doi: 10.1038/tp.2012.151

10.

Kowal

DeGiorgio

Nakaoka

Hetherington

Huerta

Diamond

Volpe

. Cognition and immunity: Antibody impairs memory. Immunity 2004; 21:179–88.

11.

Schenk

Barbour

Dunn

. Immunization with amyloid-beta attenuates Alzheimer-diseaselike pathology in the PDAPP mouse. Nature 1999; 400:173–77.

12.

Crawley

. What's wrong with my mouse: Behavioral phenotyping of transgenic and knockout mice. Hoboken, New Jersey: John Wiley & Sons; 2007.

13.

Bard

Cannon

Barbour

. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6:916–19.

14.

Hughes

. The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory. Neurosci Biobehav Rev 2004; 28:497–505.

15.

Lalonde

. The neurobiological basis of spontaneous alternation. Neurosci Biobehav Rev 2002; 26:91–104.

16.

Neff

Wei

Nolker

Bacher

Dodel

. Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders. Autoimmun Rev 2008; 7:501–7.

17.

Szabo

Relkin

Weksler

. Natural human antibodies to amyloid beta peptide. Autoimmun Rev 2008; 7:415–420.

18.

Hughes

Dalakas

Cornblath

Latov

Weksler

Relkin

. Clinical applications of intravenous immunoglobulins in neurology. Clin Exp Immunol 2009; 158(S):34–42.

19.

Relkin

Szabo

Adamiak

. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009; 30:1728–36.

20.

Racz

Nagy

Rosivall

Szebeni

Hamar

. Sugar-free, glycine-stabilized intravenous immunoglobulin prevents skin but not renal disease in the MRL/lpr mouse model of systemic lupus. Lupus 2010; 19:599–612.

21.

Chen

Lang

Zhu

Reheman

Spring

Freedman

. Animal model of fetal and neonatal immune thrombocytopenia: Role of neonatal Fc receptor in the pathogenesis and therapy. Blood 2010; 116:3660–68.

22.

Chow

Aslam

Speck

. A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell-mediated responses that are differentially sensitive to therapy. Blood 2010; 115:1247–53.

23.

Lau

Duong

Ito

Yeung

. Intravenous immunoglobulin and salicylate differentially modulate pathogenic processes leading to vascular damage in a model of Kawasaki disease. Arthritis Rheum 2009; 60:2131–41.

24.

Melnick

Rajam

Carlone

Sampson

Ades

. Evaluation of a novel therapeutic approach to treating severe pneumococcal infection using a mouse model. Clin Vaccine Immunol 2009; 16:806–10.

25.

Keren

Barshack

Pri-Chen

George

. The effect of intravenous immunoglobulins on intimal thickening in a mouse model of arterial injury. Atherosclerosis 2001; 159:77–83.

26.

Kishimoto

Takamatsu

Kawamata

Shinohara

Ochiai

. Immunoglobulin treatment ameliorates murine myocarditis associated with reduction of neurohumoral activity and improvement of extracellular matrix change. J Am Coll Cardiol 2000; 36:1979–84.